Alzheimer disease (AD) is characterized by the presence of plaques and tangles in parallel with progressive cognitive decline. The underlying cause of the cognitive decline is unknown. The purpose of this study was to identify factors that could affect learning and memory using the Tg2576 mouse model of AD. Un-biased GeneChip analysis at the time-point coinciding with the onset of behavioral deficits but prior to plaque deposition revealed that Tg2576 show altered gene expression for a number of molecules including the chemokine CXCL12. We show that this chemokine's mRNA, protein and receptor are downregulated in this mouse model coinciding with cognitive deficits. Furthermore, we demonstrate that CXCL12 levels are decreased in AD patients as compared to controls. To determine if CXCL12 might be related to impaired learning and memory, we chronically treated young nontransgenic mice with an antagonist to the CXCL12 receptor to simulate the reduction seen in transgenic animals. Treated animals showed selectively impaired learning and memory suggesting a potential role for this chemokine in cognitive functioning.
Introduction
AD is a chronic neurodegenerative disorder marked by progressive memory deterioration. Neuropathologically, two primary features characterize the disease; plaques composed of aggregated amyloid beta (Aβ) peptides and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau protein. These lesions are closely linked with chronic inflammation and synaptic/neuronal dysfunction.
The amyloid cascade hypothesis states that Aβ triggers AD and that neuropathological events occur as a consequence of Aβ accumulation (Hardy and Allsop, 1991; Selkoe, 1996) . Furthermore, the hypothesis postulates that Aβ or a consequence of its accumulation is responsible for the cognitive decline in AD. However, plaque pathology is a poor correlate of the degree of memory impairment (Braak and Braak, 1997; Crystal et al., 1988; Polvikoski et al., 2001) . Apart from plaques, soluble Aβ including oligomers such as the recently identified Aβ12mer, dubbed Aβ56*, may play a role in memory impairment. Evidence shows a robust correlation between soluble Aβ load and severity of cognitive impairment in AD (McLean et al., 1999; Wang et al., 1999) . To date, it remains unknown whether Aβ affects cognition directly through altered synaptic plasticity or may also involve a secondary effect of Aβ such as oxidative stress or inflammation.
Learning and memory are thought to depend on changes in synaptic efficacy in key brain structures including the hippocampus. Long-term potentiation (LTP) has been extensively shown as a model of use-dependent enhancement in synaptic efficacy (Bliss and Collingridge, 1993) . Deficits in LTP as a result of Aβ-soluble oligomeric species has been documented in rats in vivo (Walsh et al., 2002) as well as in hippocampal slices (Wang et al., 2002) . Interestingly, it was found that these LTP deficits induced by Aβ can be prevented by the addition of minocycline, a blocker of microglia activation (Wang et al., 2004) , suggesting that a secondary amyloiddependent mechanism may contribute to the cognitive decline in AD.
The purpose of the current study was to use the Tg2576 model to identify novel factors that might affect cognitive performance. An un-biased screen at the time-point coinciding with the onset of behavioral deficits in Tg2576 mice identified the inflammatory marker CXCL12 as a potential candidate for the behavioral deficits found in the transgenic mice. Importantly, we find that CXCL12 levels are also decreased in AD patients as compared to nondemented controls further supporting a role for this chemokine in cognitive functioning. We focused on CXCL12 for three reasons: this chemokine has been previously shown to modulate neuronal firing and neuron/glia communication (Bezzi et al., 2001; Meucci et al., 1998) , there is a characterized pharmacological agent available
